FDA Protects Patients from Harmful Drugs Through the Drug Supply Chain Security Act - fda.gov
FDA's Drug Supply Chain Security Act enhances drug safety through improved tracking and tracing of pharmaceuticals; compliance is mandatory for manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 3, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New requirements for tracking and tracing drugs throughout the supply chain to prevent harmful drugs from reaching patients.
Who it affects
All pharmaceutical manufacturers, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B).
What you must do
Implement systems for compliance with the Drug Supply Chain Security Act's tracking and tracing requirements.
Deadline
Not specified in the excerpt.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Biden administration and drug manufacturer ask court to block suspension of mifepristone approval - SCOTUSblog
- FCC Holds Calls About Free Clinical Pharmaceutical Trials Are Not “Advertising” Under the TCPA - Consumer Financial Services Law Monitor
- Strides Pharma Science Completes US-FDA Inspection, Receives Form 483 with Four Procedural Observations - scanx.trade
- Nebraska Addiction Treatment Rules Proposal - Legal Reader
- How a new FDA rule may change pharmaceutical advertising. - psychologytoday.com